Robert M. Johnson

Robert M. Johnson

Auto-generated profile, based on publicly available information

Robert M. Johnson

The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2022 in Nature
Verified
Journal Article
Closed access
PDF file
DSDavid C. Schultz
David C. Schultz
RJRobert M. Johnson
Robert M. Johnson
KAKasirajan Ayyanathan
Kasirajan Ayyanathan
JMJesse Miller
Jesse Miller
KWKanupriya Whig
Kanupriya Whig
SCSara Cherry
Sara Cherry

31 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MDMarciela M. DeGrace
Marciela M. DeGrace
EGElodie Ghedin
Elodie Ghedin
Matthew FriemanMatthew Frieman
Matthew Frieman
Florian KrammerFlorian Krammer
Florian Krammer
AGAlba Grifoni
Alba Grifoni
MSMehul Suthar
Mehul Suthar

26 January 2022 in Science Translational Medicine
Verified
Journal Article
Open access
ENEtsuro Nanishi
Etsuro Nanishi
FBFrancesco Borriello
Francesco Borriello
TOTimothy R. O’meara
Timothy R. O’meara
MMMarisa E. McGrath
Marisa E. McGrath
YSYoshine Saito
Yoshine Saito
DDDavid J. Dowling
David J. Dowling
Global deployment of vaccines that can provide protection across several age groups is still urgently needed to end the COVID-19 pandemic, especially in low- and middle-income countries. Although vaccines against SARS-CoV-2 based on mRNA and adenoviral vector technologies have been rapidly developed, additional practical and scalable SARS-CoV-2 vaccines are required to meet global demand. Protein subunit vaccines formulated with appropriate adjuvants represent an approach to address this urgent need. The receptor binding domain (RBD) is a key target of SARS-CoV-2 neutralizing antibodies but is poorly immunogenic. We therefore compared pattern recognition receptor (PRR) agonists alone or formulated with aluminum hydroxide (AH) and benchmarked them against AS01B and AS03-like emulsion-based adjuvants for their potential to enhance RBD immunogenicity in young and aged mice. We found that an AH and CpG adjuvant formulation (AH:CpG) produced an 80-fold increase in anti-RBD neutralizing antibody titers in both age groups relative to AH alone and protected aged mice from the SARS-CoV-2 challenge. The AH:CpG-adjuvanted RBD vaccine elicited neutralizing antibodies against both wild-type SARS-CoV-2 and the B.1.351 (beta) variant at serum concentrations comparable to those induced by the licensed Pfizer-BioNTech BNT162b2 mRNA vaccine. AH:CpG induced similar cytokine and chemokine gene enrichment patterns in the draining lymph nodes of both young adult and aged mice and enhanced cytokine and chemokine production in human mononuclear cells of younger and older adults. These data support further development of AH:CpG-adjuvanted RBD as an affordable vaccine that may be effective across multiple age groups.

26 May 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
BDBennett J. Davenport
Bennett J. Davenport
ACAlexis Catala
Alexis Catala
SWStuart M. Weston
Stuart M. Weston
RJRobert M. Johnson
Robert M. Johnson
JAJeremy Ardanuy
Jeremy Ardanuy
TMThomas Morrison
Thomas Morrison
The response by vaccine developers to the COVID-19 pandemic has been extraordinary with effective vaccines authorized for emergency use in the United States within 1 year of the appearance of the first COVID-19 cases. However, the emergence of SARS-CoV-2 variants and obstacles with the global rollout of new vaccines highlight the need for platforms that are amenable to rapid tuning and stable formulation to facilitate the logistics of vaccine delivery worldwide. We developed a “designer nanoparticle” platform using phage-like particles (PLPs) derived from bacteriophage lambda for a multivalent display of antigens in rigorously defined ratios. Here, we engineered PLPs that display the receptor-binding domain (RBD) protein from SARS-CoV-2 and MERS-CoV, alone (RBDSARS-PLPs and RBDMERS-PLPs) and in combination (hCoV-RBD PLPs). Functionalized particles possess physiochemical properties compatible with pharmaceutical standards and retain antigenicity. Following primary immunization, BALB/c mice immunized with RBDSARS- or RBDMERS-PLPs display serum RBD-specific IgG endpoint and live virus neutralization titers that, in the case of SARS-CoV-2, were comparable to those detected in convalescent plasma from infected patients. Further, these antibody levels remain elevated up to 6 months post-prime. In dose-response studies, immunization with as little as one microgram of RBDSARS-PLPs elicited robust neutralizing antibody responses. Finally, animals immunized with RBDSARS-PLPs, RBDMERS-PLPs, and hCoV-RBD PLPs were protected against SARS-CoV-2 and/or MERS-CoV lung infection and disease. Collectively, these data suggest that the designer PLP system provides a platform for facile and rapid generation of single and multi-target vaccines.

12 August 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
JLJames Logue
James Logue
ACArup R. Chakraborty
Arup R. Chakraborty
RJRobert Johnson
Robert Johnson
GGGirija Goyal
Girija Goyal
MRMelissa Rodas
Melissa Rodas
Matthew FriemanMatthew Frieman
Matthew Frieman
The ongoing COVID-19 pandemic has claimed more than 6 million lives and continues to test the world economy and healthcare systems. To combat this pandemic, the biological research community has shifted efforts to the development of medical countermeasures, including vaccines and therapeutics. However, to date, the only small molecules approved for the treatment of COVID-19 in the United States are the nucleoside analogue Remdesivir and the protease inhibitor Paxlovid, though multiple compounds have received Emergency Use Authorization and many more are currently being tested in human efficacy trials. One such compound, Apilimod, is being considered as a COVID-19 therapeutic in a Phase II efficacy trial. However, at the time of writing, there are no published efficacy data in human trials or animal COVID-19 models. Here we show that, while Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.

28 February 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JLJames Logue
James Logue
RJRobert M. Johnson
Robert M. Johnson
NPNita Patel
Nita Patel
BZBin Zhou
Bin Zhou
SMSonia Maciejewski
Sonia Maciejewski
Matthew FriemanMatthew Frieman
Matthew Frieman
SARS-CoV-2 variants have emerged with elevated transmission and a higher risk of infection for vaccinated individuals. We demonstrate that a recombinant prefusion-stabilized spike (rS) protein vaccine based on Beta/B.1.351 (rS-Beta) produces a robust anamnestic response in baboons against SARS-CoV-2 variants when given as a booster one year after immunization with NVX-CoV2373. Additionally, rS-Beta is highly immunogenic in mice and produces neutralizing antibodies against WA1/2020, Beta/B.1.351, and Omicron/BA.1. Mice vaccinated with two doses of Novavax prototype NVX-CoV2373 (rS-WU1) or rS-Beta alone, in combination, or heterologous prime-boost, are protected from challenge. Virus titer is undetectable in lungs in all vaccinated mice, and Th1-skewed cellular responses are observed. We tested sera from a panel of variant spike protein vaccines and find broad neutralization and inhibition of spike:ACE2 binding from the rS-Beta and rS-Delta vaccines against a variety of variants including Omicron. This study demonstrates that rS-Beta vaccine alone or in combination with rS-WU1 induces antibody-and cell-mediated responses that are protective against challenge with SARS-CoV-2 variants and offers broader neutralizing capacity than a rS-WU1 prime/boost regimen alone. Together, these nonhuman primate and murine data suggest a Beta variant booster dose could elicit a broad immune response to fight new and future SARS-CoV-2 variants.